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Introduction
Gavi, the Vaccine Alliance, finances vaccine programmes in 
low-income countries. In 2006, Gavi recognized that to reach 
high vaccine coverage levels as soon as possible, significantly, 
more funds were needed than were available. In response, 
the British Department for International Development, the 
Gates Foundation, United Nations Children’s Fund and the 
financial services industry created the independent charity, 
the International Finance Facility for Immunisation (IFFIm).
Between 2000 and 2015 two-thirds of Gavi’s funding – that 
is, 11.6 billion United States Dollars (US$) – came from dona-
tions by governments.1 Every five years governments pledge 
to donate a certain amount and then make regular payments 
to Gavi. IFFIm enables governments to make a legally bind-
ing long-term commitment to IFFIm, for example an annual 
payment of US$ 20 million for 20 years (Fig. 1), instead of 
donating directly to Gavi. Next, IFFIm creates bonds – that 
is, a type of long-term loan – to the value of the total amount 
committed by governments (in this example US$ 400 million). 
International investors then buy these bonds, thus immediately 
providing IFFIm with US$ 400 million. Gavi will have access to 
these funds by applying to IFFIm. IFFIm pays back bondhold-
ers over time with the annual payments from the governments.
The proposed benefit of IFFIm was to make the money 
from future donations available immediately, so that vaccine 
programmes could be scaled up to reach the goal of herd 
immunity earlier. However, there are two costs involved in 
this financing mechanism. First, the administration costs 
of IFFIm have been estimated between 4.1% to 4.6% of the 
pledged amount over the 20-year duration of the current 
commitments.2 Between 2010 and 2014, these costs averaged 
US$ 115 million per year, with the World Bank acting as 
treasury manager. The second cost is the payment of interest 
to bondholders, which is difficult to calculate as it depends on 
currency and market conditions.
Between 2006 and 2014, IFFIm has received in total 
US$ 6.5 billion of long-term commitments from 10 donor 
governments (Table 1) and has raised US$ 5 billion for Gavi 
through selling bonds (the difference of US$ 1.5 billion is held 
by IFFIm to reduce financial risk). Thus IFFIm has provided 
around a third of Gavi’s funding to date.1 Gavi also receives 
funding (US$ 1.5 billion) from the advanced market commit-
ment, which was an agreement by Gavi donors to pay for the 
creation of a new pneumococcal vaccine.3
In the January 2015 pledging event to secure funds for 
Gavi for 2016–2020, Gavi requested US$ 1 billion to be com-
mitted through IFFIm. However, only US$ 252 million of 
new commitments were made by France and the Netherlands 
(Table 1).4 In contrast, Gavi received all of the US$ 7.5 billion 
it had requested through direct donations. The change in 
funding profile compared to the last round – i.e. reduction of 
funds pledged through IFFIm – has been described by credit 
ratings agencies as a result of “the diminishing policy impor-
tance of IFFIm for future financing of Gavi’s immunization 
programmes”.5
Here we evaluate stakeholders’ understanding and opin-
ions of IFFIm. We also identify factors affecting funding levels 
and explore the future use of IFFIm at Gavi and for other issues 
in global health financing.
Methods
This research has been conducted and reported in compliance 
with COREQ guidelines.6 We developed a topic guide using 
existing published literature on IFFIm and related technical 
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documents for use within semi-struc-
tured interviews conducted in English 
(Box 1). The guide was piloted for suit-
ability with three staff members within 
our department. Participants were not 
restricted to the questions and were 
allowed to discuss other topics freely.
Ethical approval was received from 
the London School of Hygiene & Tropi-
cal Medicine Ethics Committee.
Sampling
We initially identified 25 stakeholders 
using the criteria in Box 2 and invited 
them to voluntarily participate by email. 
Snowball sampling was used to identify 
other suitable interviewees, leading to a 
further 74 requests being made.
Data collection and analysis
Between July and September 2015 we 
undertook 31 interviews and recorded 
22.5 hours of material, each ranging 
from 15 minutes to 43 minutes, of 
which 28 were conducted via telephone 
and three face-to-face. Two interviews 
had two participants, and 29 had one 
participant. These were transcribed and 
uploaded into Nvivo v10 (QSR Inter-
national, Cambridge, United States of 
America) for analysis using a framework 
method described elsewhere.7
One author coded all interviews 
and another author reviewed a sample of 
transcripts for accuracy. We categorized 
inductive and deductive codes by using 
a modified PESTLE framework.8 Results 
are reported using the four factors – that 
is, ideas, actor power, political contexts 
and issue characteristics – determining 
political priority described in the Shiff-
man and Smith 2007 framework.9
Results
Of the total 99 invited, 41 declined – 
either due to not having the relevant 
expertise or because they referred us 
to a more suitable person in their or-
ganization – and 25 did not respond. 
Individuals from all major stakeholder 
organizations participated, except 
the World Bank, which declined. We 
grouped organizations into categories to 
preserve the confidentiality of individual 
participants.
The final sample consisted of 33 
participants from 25 different orga-
nizations. Eight were associated with 
national government agencies and five 
were associated with nongovernmental 
organizations (NGOs). Both public–pri-
Fig. 1. Funding of Gavi, the Vaccine Alliance
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Table 1. Pledged donations to the International Finance Facility for Immunisation, 
2006–2014
Country Cumulative pledges 2006–
2014, in US$, millions (%)
Timescale, 
years
New pledges received in 
2015, in US$, millions
Australia 256 (3.9) 20 0a
Brazilb 20 (0.3) – 0
France 1899 (29.0) 20 180
Italy 635 (9.7) 20 0
Netherlands 186 (2.8) 12 72
Norway 264 (4.0) 15 0
South Africa 20 (0.3) 20 0
Spain 240 (3.7) 20 0
Sweden 38 (0.6) 15 0
United 
Kingdom
2980 (45.6) 23 0
Total 6538 (100) – 252
IFFIm: International Finance Facility for Immunisation; US$: United States dollars.
a  Australia may use IFFIm for part of its new US$ 206 million donation to Gavi, the Vaccine Alliance.
b  Brazil’s commitment is awaiting final approval.
Note: Inconsistencies arise in some values due to rounding.
Box 1. Topic guide for the interview on stakeholders’ understanding and opinions of the 
International Finance Facility for Immunisation
• Understanding of the role of IFFIm and the bond market mechanism.
• Perceived effectiveness and usefulness of IFFIm, particularly in relation to Gavi, the Vaccine 
Alliance.
• Views on factors affecting donors’ willingness to fund IFFIm.
• Views of any impact a reduction in IFFIm funding would have on Gavi.
• Views on future role for IFFIm both in relation to Gavi and more generally as a financing 
mechanism.
IFFIm: International Finance Facility for Immunisation.
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vate partnership organizations and in-
tergovernmental agency groups had four 
participants each. Three participants 
came from the pharmaceutical industry 
and two from academic institutions. 
Seven participants were not categorized 
to any group since they either no lon-
ger worked for an IFFIm stakeholder 
organization or worked for a specific 
industry that may make a participant 
identifiable if categorized separately.
Ideas
Respondents expressed varying levels 
of understanding of IFFIm as a mecha-
nism to fund vaccine programmes. 
Participants from NGOs and, to a lesser 
extent, government agencies, stated 
they lacked understanding. One NGO 
participant said:
“Personally I would really enjoy the 
ability to understand more about IFFIm 
and be able to speak about it intelligently 
and to explain … what it is and why it’s 
advantageous …”
Despite the mixed level of com-
prehension, almost all participants 
felt that IFFIm had been successful, 
particularly in its ability to raise money. 
The long-term nature of the funding 
was highly valued, as was the ability 
to front-load funds by making cash 
available up-front through accessing 
capital markets. This statement was 
supported by several comments that IF-
FIm provided Gavi with a stable, secure 
and flexible cash flow that has helped 
provide security between procurement 
and pledging cycles.
Other perceived successes men-
tioned were IFFIm’s role in increasing 
the visibility of demand and enabling 
Gavi to secure reduced prices. Par-
ticipants from across the organizational 
categories saw IFFIm funds as an impor-
tant contributing factor in Gavi being 
able to scale up coverage of vaccine 
programmes. However, this success was 
often discussed alongside the difficulty 
of separating out IFFIm’s contribution 
from Gavi’s work more generally, due 
to the pooling of funds.
Actor power
Policy community cohesion
Participants held differing views about 
the future role of IFFIm. Many par-
ticipants thought that IFFIm should 
continue to provide funds for Gavi, 
which were often expressed as a comple-
mentary mechanism to direct donations 
by providing a stable, predictable pool 
of cash to fund existing programmes. 
While other participants saw the on-
going role for IFFIm as being ready to 
generate funds to finance new vaccines 
– such as Ebola and malaria vaccines. 
Several people stated that they felt IFFIm 
had served its purpose to capitalize Gavi 
in its start-up phase and should now 
slowly be phased out after meeting its 
bond commitments.
Several commented that a reduction 
in IFFIm funds would have negative 
impacts on Gavi, including: reduced 
funding predictability and potential for 
cash flow problems; increased risk of a 
slower response to emerging vaccine 
issues; reduced ability to deliver vaccine 
programmes; and an adverse effect on 
vaccine prices. However, others thought 
it would have no impact, largely because 
Gavi had been fully replenished through 
direct donations.
Three participants from donor 
governments said that IFFIm was seen 
as maintaining an older way of providing 
official development assistance. Lately, 
however, donor governments have em-
phasized the need for recipient countries 
to assume more responsibility for their 
spending on health.
Leadership and institutions
The IFFIm board was generally seen as 
effective at managing the bond financing 
mechanism. Historically, the British De-
partment for International Development 
had led the creation and establishment 
of IFFIm and has been its biggest funder 
to date. However, participants saw the 
department’s policy as having changed 
from using IFFIm to fund Gavi, to now 
giving donations directly to Gavi, thus 
affecting IFFIm funding levels. Partici-
pants hypothesized this was due to the 
availability of funds resulting from the 
increased commitment of the British 
Government to spend 0.7% of Gross 
National Income on international 
development. More broadly, however, 
participants thought the department 
had not maintained the political will to 
advocate for IFFIm.
Civil society mobilization
Participants from both NGOs and 
governments stated that Gavi had not 
actively advocated for pledges to be 
made through IFFIm around the time 
of the pledging meeting in January 
2015. Participants from government 
agencies explained that securing the 
required long-term agreements was a 
burdensome process and they would be 
unlikely to spontaneously undertake this 
without additional support from Gavi or 
encouragement from the NGO sector.
Political contexts
Policy windows
Participants described a clear policy 
window in 2006 that brought together 
actors to establish IFFIm, with a drive 
to scale up vaccine programmes to meet 
the millennium development goals. 
However, this window closed following 
the 2008 financial crisis and the subse-
quent change in the macro-economic 
environment. All participants discussed 
the profound impact the crisis had on 
the policies of national governments. 
One participant from an intergovern-
mental agency stated:
“I do wonder the extent to which the 
notion of innovative financing … 
particularly government bond-funded 
investments … are much less appealing 
now in 2015 than they [were] in 2006 
through 2008 … primarily because of 
Box 2. Criteria for identifying stakeholders of the International Finance Facility for 
Immunisation
1.  Stakeholders currently or historically involved with the function, administration or delivery 
of IFFIm were identified from document analysis of meeting attendance records.
2.  Stakeholders from organizations who have donated to or received disbursements from IFFIm 
were identified from the IFFIm and Gavi, the Vaccine Alliance, websites.
3.  Stakeholders from organizations representing people who have been beneficiaries of 
IFFIm funds were identified from the IFFIm and Gavi websites, especially the civil society 
organizations’ group.
4.  Stakeholders who are currently doing research on financing global vaccine programmes or 
who have a historical research or policy interest in IFFIm were identified from publications 
in the academic and grey literature.
IFFm: International Finance Facility for Immunisation.
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the financial crisis that everyone lived 
through …”
Donors were seen as less likely to 
pledge to IFFIm after the financial crisis, 
because of the implementation of fis-
cal austerity in many donor countries. 
Participants from governments also 
expressed a preference for not being 
locked into multi-year commitments.
Government participants expressed 
divergent views on their intention to 
fund IFFIm in the future. Some donor 
governments intended to continue to 
fund IFFIm at their current level, while 
others did not plan to make any future 
commitments. Two governments were 
keen to increase their contributions and 
one was interested in pledging to IFFIm 
in the future, but had not done so in the 
past. Additionally, some participants 
thought that the likely global pool of 
donors had been saturated, particularly 
as budgetary cycles in Japan and the 
USA prevent long-term commitments.
Global governance structure
The nature of global vaccine finance 
has changed over time, particularly as 
Gavi has become a more established 
organization. Participants described 
Gavi as now being independently suc-
cessful and leading the vaccine policy 
agenda. As a result, donors now prefer to 
donate directly rather than through IF-
FIm, which participants highlighted by 
the fact that Gavi was fully replenished. 
One participant from a public–private 
partnership said:
“They’ve been a victim of their own 
success … countries like giving money 
to Gavi and … historically Gavi’s ended 
up slightly overfunded … and when it 
has been overfunded … there’s no point 
borrowing out of IFFIm because … the 
money [is] in [its] own bank account.”
Issue characteristics
Many participants discussed the im-
portant role IFFIm funds had played 
in enabling Gavi to scale up vaccine 
programmes in low-income countries. 
However, overall participants expressed 
doubt about whether IFFIm continued 
to be relevant.
Many felt that they did not have 
enough information on IFFIm’s perfor-
mance. Some commented that they had 
not seen an evaluation. These comments 
were especially common among partici-
pants from NGOs and pharmaceutical 
industries, and to a lesser extent among 
the government participants. Those who 
were familiar with the independent 2011 
evaluation2 felt that the report may need 
to be updated or its findings better com-
municated to stakeholders.
Several participants expressed 
uncertainty or concern about the costs 
of the management and administration 
of raising funds through the bond mar-
kets. While others thought that these 
costs were relatively low, all questioned 
whether this was cost–effective. Some 
participants, including from govern-
ments, discussed the complications 
arising from the downgrade of countries’ 
credit ratings and the subsequent impact 
on cost of borrowing from the capital 
markets.
Bond financing
Many participants felt that bond financ-
ing could be beneficial for other global 
health or development issues. The most 
common proposals included: raising 
funds swiftly from pledges made in the 
face of emergency disease epidemics 
or in the event of a disaster; for the 
procurement of commodities such as 
drugs, technologies or bednets, which 
was framed both as an incentive for 
research and development, but also to 
provide security to companies produc-
ing the items; or to fund eradication 
programmes for specific diseases. How-
ever, it was pointed out that eradication 
programmes might not be an ideal can-
didate as they often have long, expensive 
end phases to eradicate the final cases 
(e.g. polio).
Other potential proposals men-
tioned were climate change and educa-
tion, but many comments were scepti-
cal, as the participants perceived the 
required interventions to be unclear or 
controversial. Water and sanitation were 
discussed more favourably, particu-
larly to fund the initial infrastructure 
of pumps and pipes, while noting that 
these would require long-term funding 
for maintenance.
Discussion
In the interviews stakeholders de-
scribed changes related to each of the 
four factors that affect whether a global 
health issue, like financing vaccine 
programmes, is considered a political 
priority. First, IFFIm now exists within 
a different political context following 
the 2008 financial crisis and the effect 
this had on the financial position of 
donor governments. Second, in terms 
of the important ideas relating to IF-
FIm, stakeholders expressed uncertainty 
about the proposed benefits. Third, the 
characteristics of the issue have changed, 
with scaling up vaccine programmes us-
ing IFFIm funds seen as less of a priority 
now than in 2006, particularly as the 
cost–benefit trade-off of raising funds 
through IFFIm is not well understood 
by stakeholders. Finally, the power of 
actors has changed in relation to IFFIm, 
with disagreements identified among 
participants on the future use of IFFIm 
to raise funds and a reduced interest 
from civil society groups. Together, 
the changes described by stakeholders 
in relation to the four factors provide 
a possible explanation why there were 
fewer commitments in the January 2015 
pledging conference.
The participants had divergent 
views about IFFIm’s on-going role. 
Overall IFFIm was seen as having been 
successful in a wide variety of ways, 
including accessing new funds and influ-
encing the vaccine market, which have 
led to an expectation that IFFIm will 
continue in a similar role. IFFIm also 
provides security and confidence to the 
pharmaceutical industry, as the cost of 
delivering vaccine programmes is likely 
to increase, since the cost has already 
risen with the addition of new vaccines 
from US$ 0.67 in 2001 to US$ 45.59 in 
2014.10 Using IFFIm funds to smooth 
out the procurement cycle reduces Gavi’s 
dependence on the receipt of donated 
funds, which is known to cause difficul-
ties in other similar organizations, such 
as ensuring timely payment for supply 
of goods.11 However, participants high-
lighted that Gavi was fully replenished 
through direct donations in its most 
recent funding round, suggesting ad-
ditional front-loaded funds may not 
be required. Since Gavi did not request 
any funds from IFFIm in 2014 there is 
currently a surplus in IFFIm,1 leading 
some participants to question IFFIm’s 
future relevance.
Participants were also unsure of 
the financing and management costs. 
At inception, most donor countries 
had the highest credit ratings (AAA), 
however some ratings have been succes-
sively downgraded, which could make 
raising funds through bond issuances 
more difficult or expensive.12 IFFIm has 
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not experienced such problems since it 
continues to issue bonds at competitive 
rates, although this has not been com-
municated well to stakeholders. How-
ever, if AAA rated donors stop funding 
IFFIm, the costs of issuing bonds with 
only low-rated donors will be much 
higher. If funding is to be maintained, 
then IFFIm and Gavi will need to 
provide additional evidence of IFFIm’s 
cost–benefit trade-off and be sensitive to 
the differing circumstances and priori-
ties of government donors.
IFFIm-like mechanisms have been 
proposed to fund a wide range of other 
global health issues, including malaria 
control, Ebola vaccine and noncom-
municable diseases.13–15 More broadly, 
IFFIm has also been proposed as a pos-
sible mechanism to raise funds to meet 
the sustainable development goals and 
the outcome document for the Third 
International Conference on Financing 
For Development, explicitly encourages 
the development of IFFIm-like mecha-
nisms.16,17 There are several unique 
features about vaccine programmes 
that could make transferability of an 
IFFIm-like mechanism to other areas 
challenging.12 However, participants 
highlighted two circumstances where 
the use of an IFFIm-type mechanism 
may be appropriate.
First, bond financing could have 
a role in emergency preparedness, 
including disasters and pandemics. In 
the context of a pledging conference 
to urgently raise funds for a natural 
disaster or infectious disease outbreak, 
an IFFIm-like mechanism could be 
used to generate the cash from donor 
pledges relatively quickly rather than 
waiting for them to be mobilized over 
time. A recent study found that of the 
US$ 2.89 billion pledged to combat the 
2013–2016 Ebola virus disease outbreak, 
only US$ 1.09 billion had been collected 
by mid-2015.18 If bond financing had 
been used, funds might have been avail-
able closer to the time when they were 
most needed.
Second, bond financing could 
support quantifiable, outcomes-based, 
time-limited interventions, including 
the formation of a new organization or 
delivery of a specific intervention, for 
example a catch-up vaccination pro-
gramme. The risk of using front-loaded 
funds for programmes with on-going 
costs – such as maintenance or staffing – 
is that the benefit of an increase in infra-
structure is negated by its deterioration 
or disrepair without sustainable funding 
once the initial funds have been spent.
Any new bond financing initiative 
should have well-defined objectives and 
quantifiable outcomes to ensure that its 
cost–effectiveness can be evaluated. One 
example of this is when organizations 
release social impact bonds which are 
bonds sold to investors to generate funds 
for development projects that have clear 
evaluation criteria and are highly out-
comes focused.19 Another example is the 
development impact bonds released by 
the British Department for International 
Development to fund African sleeping 
sickness prevention programmes.20 
Unlike IFFIm bonds, investors are only 
repaid if the programme funded is suc-
cessful. This increases the risk to bond-
holders of not being repaid, but also 
increases buy-in from the private sector 
organizations that buy the bonds, who 
are motivated to ensure the programmes 
are successful.21
This study has limitations. The 
sample may suffer from volunteer bias 
and is unlikely to cover the full range 
of views relating to IFFIm. The World 
Bank declined, as did a small number 
of government agencies, notably those 
from low-income countries. Several 
NGOs, both international and local, 
could not identify a relevant member 
of staff to participate.
In conclusion, IFFIm is unique 
in international development finance 
and is seen as successful by many 
stakeholders. However, the benefit of 
pledging funds through IFFIm needs 
to be re-evaluated and communicated 
to stakeholders. The IFFIm financing 
mechanism has the potential to raise 
funds for other global health issues. 
However these issues must be carefully 
considered as to whether bond financing 
could be effective and must have quan-
tifiable pre-defined outcome indicators 
to evaluate performance. ■
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صخلم
ةينعلما تاهلجا رظن تاهجو :ينصحتلل ليودلا ليومتلا قفرم
 قفرمب  ةصالخا  ءارلآاو  ةينعلما  تاهلجا  مهف  ةجرد  مييقت  ضرغلا
 لىع ةرثؤلما لماوعلا ديدحتل ؛)IFFIm( ينصحتلل ليودلا ليومتلا
 نم  ةيلبقتسلما  ةدافتسلاا  ىدم  فاشكتسلاو  ؛ليومتلا  تايوتسم
.ينصحتلل ليودلا ليومتلا قفرم
 2015 ماع نم برمتبسو ويلوي يرهش ينب ام ةترفلا في انمق ةقيرطلا
 اهنع فيرعتلا متي ةمظنم 25 نولثمي اًدرف 33 عم تلاباقم ءارجإب
 متو  .ينصحتلل  ليودلا  ليومتلا  قفرم  في  ةينعم  تاهج  اهرابتعاب
 هبش تلاباقلما نم ةعاس 22.5 هعوممج ام ليلتحو خسنو ليجست
.يماظنلا لمعلا ةقيرط مادختساب ةننقلما
 ةعباتلا  ليومتلا  ةيللآ  ةينعلما  تاهلجا  مهف  ةجرد  تفلتخا  جئاتنلا
 تبغرو  اهيلع  ةبتترلما  جئاتنلاو  ينصحتلل  ليودلا  ليومتلا  قفرلم
 ماقو  .تامولعلما  نم  ديزلما  ةفرعم  في  ةينعلما  تاهلجا  نم  ديدعلا
 ةيلكلا ةيداصتقلاا ةئيبلا في يريغتلا نأ لىع ءوضلا طيلستب نوكراشلما
 ةسايسلا لىع رثأ 2008 ماع في ةيلالما ةمزلأا باقعأ في ثدح يذلا
 ةديدلجا  تامازتللاا  ددع في رثأ  لياتلابو  ةحنالما  لودلا  في ةينطولا
 Gavi ةمظنم نأ ماب .ينصحتلل ليودلا ليومتلا قفرم اهملتسا يتلا
 نوكراشلما  دكأ  دقف  ،ةروطتمو  ةحجان  ةمظنم  نلآا  اهرابتعا  متي
 ةعانص تماق .Gavi لىإ ةشرابم عبرتلا نولضفي ينعبرتلما نأ لىع
 هيرفوتل  ينصحتلل  ليودلا  ليومتلا  قفرم  ريدقتب  ةيئاودلا  تاجتنلما
 ةينعلما  تاهلجا  تماق  ماك  .ليومتلا  في  ةنورلماو  رارقتسلاا  لماوع
 هلوصح ةيناكملإ ينصحتلل ليودلا ليومتلا قفرم ريدقتب ىرخلأا
 .حيقلتلا ةيطغت ةدايز نم Gavi ةمظنم ينكتمو اًركبم لاوملأا لىع
 ليودلا  ليومتلا  قفرم  نأب  ةينعلما  تاهلجا  تدقتعا  ،ماع  لكشب
 رودلا لوح ةنيابتم ًءارآ ميهدل تناك نكلو ،اًحجان ناك ينصحتلل
 ركذب  نوكراشلما  ماق  .ينصحتلل  ليودلا  ليومتلا  قفرلم  رمتسلما
 ةبسانم تادنسلا بجومب ليومتلا تايلآ برتعت نأ نكمي ينتلكشم
 ةدودحلما  تلاخدتلاو  ئراوطلا  تلاالح  بهأتلا  :اهمو  اهللح
.تلاصحلما لىع ةمئاقلاو نمزلاب
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 للاخ نم لاوملأاب عبرتلا ةدئاف مييقت ةداعلإ ةجاح كانه جاتنتسلاا
 تامادختسلاا نم ديدعلا  كانه .ينصحتلل ليودلا  ليومتلا  قفرم
 لح  فدبه  لاوملأا  عملج  تادنسلا  بجومب  ليومتلل  ةلمتحلما
 هذه  ةاعارم  يغبني  نكلو  ،ىرخلأا  ةيلماعلا  ةيحصلا  تلاكشلما
 تاشرؤم عم ،ةيلاعفلا قيقحتل يرياعلما لباقم ةيانعب تامادختسلاا
 .ءادلأا مييقتل سايقلل ةلباقلاو اًقبسم ةددحلما جئاتنلا
摘要
国际免疫融资机制：利益相关者的视角
目的 评价利益相关者对国际免疫融资机制 (IFFIm) 的
理解和看法 ；确定影响资金水平的因素 ；以及探讨国
际免疫融资机制 (IFFIm) 的未来用途。
方法 在 2015 年 7 月 至 9 月 期 间， 我 们 采 访 了 来
自 25 个机构的 33 位确认为国际免疫融资机制 (IFFIm) 
利益相关者的人员。使用框架法录音、记录和分析了
共耗时 22.5 小时的半结构式访谈。
结果 利益相关者对国际免疫融资机制 (IFFIm) 的融资
机制和结果的理解各不相同，并且，许多利益相关者
希望获得更多信息。参与者强调，2008 年金融危机之
后的宏观经济环境变化影响了援助国的国家政策，进
而影响了国际免疫融资机制 (IFFIm) 收到的新捐款的
数目。由于全球疫苗免疫联盟 (Gavi) 目前被视为一个
成功且成熟的机构，参与者表明援助国更愿意直接向
全球疫苗免疫联盟 (Gavi) 捐款。制药行业因资金的稳
定性和灵活性而非常重视国际免疫融资机制 (IFFIm)。
其它利益相关者则重视国际免疫融资机制 (IFFIm) 能
够较早获取资金并促使全球疫苗免疫联盟 (Gavi) 增加
疫苗覆盖范围的能力。整体来说，利益相关者认为国
际免疫融资机制 (IFFIm) 是成功的，但是对其今后的
角色，他们意见不一。参与者列出了两处可能需要债
券融资机制的问题领域 ：应急准备和基于结果的限时
干预措施。
结论 需要对通过国际免疫融资机制 (IFFIm) 筹集资金
的优势进行重新评估。债券融资在其他全球性卫生问
题的融资上有潜在用途，但是我们必须根据标准对其
进行仔细斟酌以提高效率，并通过可量化的预定义成
果指标评估其表现。
Résumé
La Facilité financière internationale pour la vaccination: points de vue des parties prenantes
Objectif Évaluer la compréhension et l’opinion qu’ont les parties 
prenantes sur la Facilité financière internationale pour la vaccination 
(International Finance Facility for Immunisation / IFFIm); identifier les 
facteurs qui influent sur les niveaux de financement; et s’interroger sur 
l’utilisation future de l’IFFIm.
Méthodes Entre juillet et septembre 2015, nous avons interrogé 
33 membres provenant de 25 organisations identifiées comme des 
parties prenantes de l’IFFIm. Au total, 22,5 heures d’entretiens semi-
structurés ont été enregistrées, transcrites et analysées en utilisant une 
méthode de cadre.
Résultats La perception par les parties prenantes du mécanisme 
de financement de l’IFFIm et de ses résultats est variable, et nombre 
de parties prenantes souhaiteraient avoir plus d’informations. Les 
participants ont souligné le fait que le changement de l’environnement 
macroéconomique survenu après la crise financière de 2008 a affecté 
les politiques nationales dans les pays donateurs et par conséquent le 
nombre de nouveaux engagements reçus dans le cadre de l’IFFIm. Étant 
donné que Gavi- L’Alliance du vaccin est aujourd’hui considérée comme 
une organisation arrivée à maturité et une réussite, les participants 
ont indiqué que les bailleurs de fonds préfèrent désormais donner 
directement à Gavi. Pour sa part, l’industrie pharmaceutique apprécie 
l’IFFIm parce qu’elle permet à la fois une stabilité des financements et 
de la souplesse. D’autres parties prenantes apprécient le fait que l’IFFIm 
permette d’accéder rapidement à des fonds et qu’elle permette à Gavi 
d’améliorer la couverture vaccinale. De manière générale, les parties 
prenantes estiment que l’IFFIm est un succès, même si leur opinion 
diverge quant au rôle de l’IFFIm à l’avenir. Les participants ont évoqué 
deux applications pour lesquelles des mécanismes de financement 
obligataire pourraient être appropriés: les plans d’intervention d’urgence 
et des interventions orientées-résultats et limitées dans le temps.
Conclusion Il est nécessaire de réévaluer les avantages des fonds 
récoltés par l’IFFIm. Des financements obligataires pourraient être 
utilisés pour lever des fonds pour d’autres enjeux sanitaires mondiaux. 
Mais ces utilisations potentielles devront être attentivement considérées 
au regard de critères permettant de déterminer leur efficacité et en 
prévoyant des indicateurs de résultats quantifiables pour évaluer leur 
performance.
Резюме
Международный механизм финансирования иммунизации: мнение заинтересованных лиц
Цель Оценить понимание заинтересованными лицами 
Международного механизма финансирования иммунизации 
(ММФИ) и их мнения о нем, определить факторы, влияющие 
на уровень финансирования, и изучить возможности будущего 
применения ММФИ.
Методы В период между июлем и сентябрем 2015 года 
были проинтервьюированы 33 человека из 25 организаций, 
определенных в качестве сторон, заинтересованных в 
ММФИ. В общей сложности было записано, расшифровано и 
проанализировано с помощью матричного метода 22,5 часа 
полуструктурированных интервью.
Результаты  Понимание заинтересованными лицами 
ММФИ и его результатов было неодинаковым, и многим 
заинтересованным лицам требовалась дополнительная 
информация. Интервьюируемые отметили, что изменение 
макроэкономического климата после финансового кризиса 2008 
года повлияло на национальную политику в странах-донорах и, 
как следствие, на количество новых обязательств, полученных 
ММФИ. Поскольку Gavi в настоящий момент считается успешной 
и устоявшейся организацией, интервьюируемые заявили, что 
доноры предпочитают предоставлять средства напрямую 
этой организации. Представители фармацевтической отрасли 
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отметили полезность ММФИ в плане обеспечения стабильного 
и гибкого финансирования. Другие заинтересованные лица 
оценили то, что с помощью ММФИ можно заблаговременно 
получать доступ к финансам и что благодаря ему Gavi удалось 
увеличить охват вакцинации. В целом заинтересованные лица 
признали успешность ММФИ, но расходились во взглядах 
относительно его текущей роли. Интервьюируемые назвали две 
сферы, в которых механизмы облигационного финансирования 
могут быть целесообразны: готовность к чрезвычайным 
ситуациям и основанные на результатах, ограниченные во 
времени вмешательства.
Вывод Необходима повторная оценка преимущества 
предоставления финансов посредством ММФИ. Облигационное 
финансирование потенциально может быть использовано для 
привлечения инвестиций с целью решения других проблем 
международного здравоохранения, однако для каждого такого 
случая необходимо рассматривать целесообразность его 
применения с точки зрения эффективности, рассчитываемой 
с помощью предварительно устанавливаемых, поддающихся 
количественному измерению показателей результативности. 
Resumen
El Fondo Financiero Internacional para la Inmunización: opiniones de los participantes
Objetivo Evaluar el conocimiento y las opiniones de los participantes 
del Fondo Financiero Internacional para la Inmunización (FFII), identificar 
los factores que afectan los niveles de financiación y explorar el futuro 
uso del FFII.
Métodos Entre julio y septiembre de 2015, se entrevistó a 33 individuos 
de 25 organizaciones identificadas como participantes del FFII. En 
total, se grabaron, transcribieron y analizaron 22,5 horas de entrevistas 
semiestructuradas utilizando un método de marco.
Resultados El conocimiento de los participantes sobre el mecanismo 
de financiación del FFII y sus resultados varió y muchos de ellos querían 
más información. Los participantes destacaron que el cambio del 
entorno macroeconómico tras la crisis financiera de 2008 perjudicó a 
la política nacional de países donantes y, posteriormente, el número de 
nuevos compromisos que recibió el FFII. Puesto que ahora la Gavi está 
considerada como una organización madura y de éxito, los participantes 
declararon que los donantes prefieren donar directamente a la Gavi. La 
industria farmacéutica valoró el FFII por ofrecer estabilidad y flexibilidad 
de financiación. Otros participantes valoraron la capacidad del FFII 
para tener acceso rápido a los fondos y permitir a la Gavi aumentar la 
cobertura de la vacunación. En general, los participantes pensaron que 
el FFII tenía éxito, pero tenían opiniones diferentes sobre el papel actual 
de dicho Fondo. Enumeraron dos asuntos para los que los mecanismos 
de financiación de bonos podrían ser adecuados: la preparación de 
emergencia y las intervenciones en un tiempo limitado basadas en 
los resultados.
Conclusión Se deben volver a evaluar los beneficios de otorgar fondos 
a través del FFII. Existen posibles usos para los que la financiación de 
bonos aumente los fondos para abordar otros problemas sanitarios 
globales, pero es necesario analizarlos en profundidad frente a los 
criterios para establecer la eficacia, con indicadores cuantificables de 
resultados predefinidos para evaluar el rendimiento.
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